Xue, Lulu https://orcid.org/0000-0001-5719-1336
Zhao, Gan https://orcid.org/0000-0002-8043-6036
Gong, Ningqiang https://orcid.org/0000-0002-9444-8505
Han, Xuexiang https://orcid.org/0000-0003-0011-5222
Shepherd, Sarah J.
Xiong, Xinhong
Xiao, Zebin https://orcid.org/0000-0002-3311-7403
Palanki, Rohan
Xu, Junchao https://orcid.org/0000-0003-0725-8111
Swingle, Kelsey L. https://orcid.org/0000-0001-8475-9206
Warzecha, Claude C. https://orcid.org/0000-0002-3659-2867
El-Mayta, Rakan https://orcid.org/0000-0002-5855-233X
Chowdhary, Vivek https://orcid.org/0000-0003-1277-0128
Yoon, Il-Chul
Xu, Jingcheng
Cui, Jiaxi
Shi, Yi https://orcid.org/0000-0002-9084-8069
Alameh, Mohamad-Gabriel https://orcid.org/0000-0002-5672-6930
Wang, Karin https://orcid.org/0000-0001-7812-2583
Wang, Lili https://orcid.org/0000-0001-9347-3939
Pochan, Darrin J.
Weissman, Drew
Vaughan, Andrew E. https://orcid.org/0000-0001-5740-643X
Wilson, James M. https://orcid.org/0000-0002-9630-3131
Mitchell, Michael J. https://orcid.org/0000-0002-3628-2244
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (DP2 TR002776)
Article History
Received: 9 April 2023
Accepted: 8 July 2024
First Online: 1 October 2024
Competing interests
: L.X. and M.J.M. are inventors on a patent filed by the Trustees of the University of Pennsylvania (International Patent Application No. PCT/US23/66564) describing the lipid nanoparticle technology in this study. J.M.W. is a paid advisor to and holds equity in iECURE, Passage Bio and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies and Ceva Santé Animale. He has sponsored research agreements with Alexion Pharmaceuticals, Amicus Therapeutics, CBM, Ceva Santé Animale, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE and Passage Bio, which are licensees of Penn Technology. J.M.W., L.W. and C.C.W are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. D.W. is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. M.J.M., D.W. and M.-G.A. are also named on patents describing the use of lipid nanoparticles and lipid compositions for nucleic acid delivery. The other authors declare no competing interests.